Stem Cell Transplant for Blood Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide (PTCy) at 40mg/kg, tacrolimus and MMF for GVHD prophylaxis.
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Preparative Regimen
Participants receive Treosulfan and Fludarabine preparative regimen followed by stem cell infusion
Post-Transplant
Participants receive post-transplant cyclophosphamide (PTCy), tacrolimus, and MMF for GVHD prophylaxis
Follow-up
Participants are monitored for overall survival and transplant-related mortality
What Are the Treatments Tested in This Trial?
Interventions
- Cyclophosphamide
- Fludarabine
- Treosulfan
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Subjects treated with Treosulfan and Fludarabine preparative regimen with TBI for AML and MDS patients followed by a related or unrelated donor stem cell infusion utilizing PTCy, tacrolimus and MMF as GVHD prophylaxis.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Masonic Cancer Center, University of Minnesota
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.